These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 6097439)

  • 1. Adrenocortical carcinoma responded to treatment with o,p'-DDD--a case report.
    Naruse T; Koike A; Kato K; Ishii T; Suzumura K; Matsumoto K
    Endocrinol Jpn; 1984 Aug; 31(4):417-26. PubMed ID: 6097439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The effects of o,p'-DDD on human adrenal steroid synthesis].
    Ojima M; Saito M; Fukuchi S
    Nihon Naibunpi Gakkai Zasshi; 1984 Jul; 60(7):852-71. PubMed ID: 6094274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significant regression of the tumor combined with the high level of plasma cortisol by low-dose administration of O, p'-DDD in a case with Cushing's syndrome caused by adrenocortical carcinoma.
    Otokida K; Nakamura M; Takeda M; Ito T; Kato M; Masuda T; Tashiro A
    Tohoku J Exp Med; 1986 Dec; 150(4):407-15. PubMed ID: 3564003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recovery of adrenal function after treatment of adrenocortical carcinoma with o,p'-DDD.
    Greig F; Oberfield SE; Levine LS; Ghavimi F; Pang S; New MI
    Clin Endocrinol (Oxf); 1984 Apr; 20(4):389-99. PubMed ID: 6325050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of adrenal cortical carcinoma with mitotane: outcome and complications.
    Lim MC; Tan YO; Chong PY; Cheah JS
    Ann Acad Med Singap; 1990 Jul; 19(4):540-4. PubMed ID: 2171414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapy of the adrenocortical carcinoma with Lysodren (o,p'-DDD). Therapeutic management by monitoring o,p'-DDD blood levels].
    Heilmann P; Wagner P; Nawroth PP; Ziegler R
    Med Klin (Munich); 2001 Jul; 96(7):371-7. PubMed ID: 11494911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical results of the use of mitotane for adrenocortical carcinoma.
    Kasperlik-Zaluska AA
    Braz J Med Biol Res; 2000 Oct; 33(10):1191-6. PubMed ID: 11004719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A high-pressure liquid chromatographic method for measuring mitotane [1,1-(o,p'-Dichlorodiphenyl)-2,2-dichloroethane] and its metabolite 1,1-(o,p'-Dichlorodiphenyl)-2,2-dichloroethene in plasma.
    Andersen A; Warren DJ; Nome O; Vesterhus L; Slørdal L
    Ther Drug Monit; 1995 Oct; 17(5):526-31. PubMed ID: 8585118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines.
    Cerquetti L; Bucci B; Marchese R; Misiti S; De Paula U; Miceli R; Muleti A; Amendola D; Piergrossi P; Brunetti E; Toscano V; Stigliano A
    Endocr Relat Cancer; 2008 Jun; 15(2):623-34. PubMed ID: 18509009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete response of metastatic adrenal cortical carcinoma to o,p'-DDD in a child.
    Krzisnik C; Petric G; Jereb B
    Pediatr Hematol Oncol; 1988; 5(1):65-9. PubMed ID: 3152953
    [No Abstract]   [Full Text] [Related]  

  • 11. Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma?
    Dickstein G; Shechner C; Arad E; Best LA; Nativ O
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3100-3. PubMed ID: 9745410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of o,p'-DDD on adrenal steroid replacement therapy requirements.
    Robinson BG; Hales IB; Henniker AJ; Ho K; Luttrell BM; Smee IR; Stiel JN
    Clin Endocrinol (Oxf); 1987 Oct; 27(4):437-44. PubMed ID: 2830062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitotane effects in a H295R xenograft model of adjuvant treatment of adrenocortical cancer.
    Lindhe O; Skogseid B
    Horm Metab Res; 2010 Sep; 42(10):725-30. PubMed ID: 20665429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of serum-free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study.
    Alexandraki KI; Kaltsas GA; le Roux CW; Fassnacht M; Ajodha S; Christ-Crain M; Akker SA; Drake WM; Edwards R; Allolio B; Grossman AB
    Clin Endocrinol (Oxf); 2010 Mar; 72(3):305-11. PubMed ID: 19473175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bovine adrenal cortex transformations of mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; o,p'-DDD] and its p,p'- and m,p'-isomers.
    Cai W; Benitez R; Counsell RE; Djanegara T; Schteingart DE; Sinsheimer JE; Wotring LL
    Biochem Pharmacol; 1995 May; 49(10):1483-9. PubMed ID: 7763292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma.
    Kroiss M; Plonné D; Kendl S; Schirmer D; Ronchi CL; Schirbel A; Zink M; Lapa C; Klinker H; Fassnacht M; Heinz W; Sbiera S
    Eur J Endocrinol; 2016 Mar; 174(3):343-53. PubMed ID: 26671975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The distribution of o,p'-DDD (mitotane) among serum lipoproteins in normo- and hypertriglyceridemia.
    Gebhardt DO; Moolenaar AJ; van Seters AP; van der Velde EA; Gevers Leuven JA
    Cancer Chemother Pharmacol; 1992; 29(4):331-4. PubMed ID: 1537084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of adrenolytic mitotane on drug elimination pathways assessed in vitro.
    Theile D; Haefeli WE; Weiss J
    Endocrine; 2015 Aug; 49(3):842-53. PubMed ID: 25542188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. o,p'-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement.
    Hogan TF; Citrin DL; Johnson BM; Nakamura S; Davis TE; Borden EC
    Cancer; 1978 Nov; 42(5):2177-81. PubMed ID: 719602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete response of metastasized adrenal cortical carcinoma with o,p'-DDD. Case report and literature review.
    Boven E; Vermorken JB; van Slooten H; Pinedo HM
    Cancer; 1984 Jan; 53(1):26-9. PubMed ID: 6360329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.